



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION

Clone ID	DMC680
Target	CXCR4
Synonyms	CD184; D2S201E; FB22; HM89; HSY3RR; LAP-3; LAP3; LCR1; LESTR; NPY3R; NPYR; NPYRL; NPY3R; WHIM; WHIMS
Host Species	Rabbit
Description	PE-conjugated Anti-CXCR4 antibody(DMC680), IgG1 Chimeric mAb
Delivery	Under Development
Uniprot ID	P61073; A0A0U3FJG0; A0A0U3GXA9
IgG type	Rabbit/Human Fc chimeric IgG1
Clonality	Monoclonal
Reactivity	Human
Applications	Flow Cyt
Recommended Dilutions	Flow Cyt 1:100
Purification	Purified from cell culture supernatant by affinity chromatography
Formulation & Reconstitution	Liquid□PBS with 0.05% Proclin300, 1% BSA
Storage & Shipping	Store at 2°C-8°C for 6 months
Background	This gene encodes a CXC chemokine receptor specific for stromal cell-derived factor-1. The protein has 7 transmembrane regions and is located on the cell surface. It acts with the CD4 protein to support HIV entry into cells and is also highly expressed in breast cancer cells. Mutations in this gene have been associated with WHIM (warts; hypogammaglobulinemia; infections; and myelokathexis) syndrome. Alternate transcriptional splice variants; encoding different isoforms; have been characterized. [provided by RefSeq; Jul 2008]
Usage	Research use only
Conjugate	PE-conjugated
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

